Analysts See $0.01 EPS for IntelliPharmaCeutics Intl Inc (USA) (IPCI)

September 17, 2017 - By Henry Gaston

 Analysts See $0.01 EPS for IntelliPharmaCeutics Intl Inc (USA) (IPCI)

Analysts expect IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) to report $0.01 EPS on October, 12.They anticipate $0.08 EPS change or 114.29 % from last quarter’s $-0.07 EPS. IPCI’s profit would be $312,383 giving it 24.03 P/E if the $0.01 EPS is correct. After having $-0.06 EPS previously, IntelliPharmaCeutics Intl Inc (USA)’s analysts see -116.67 % EPS growth. The stock decreased 3.95% or $0.039 on September 15, reaching $0.961. About 214,950 shares traded. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has risen 16.57% since September 17, 2016 and is uptrending. It has underperformed by 0.13% the S&P500.

Intellipharmaceutics International Inc is a Canada pharmaceutical firm engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The company has market cap of $30.02 million. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It currently has negative earnings. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular.

More notable recent IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) news were published by: Globenewswire.com which released: “Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported …” on July 31, 2017, also Seekingalpha.com with their article: “IntelliPharmaCeutics International – Very Low Downside And Huge Upside” published on July 25, 2017, Marketwatch.com published: “0.9767” on November 12, 2010. More interesting news about IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) were released by: Globenewswire.com and their article: “Intellipharmaceutics Provides Operational Update” published on September 05, 2017 as well as Globenewswire.com‘s news article titled: “Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista …” with publication date: April 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: